Macrogenics Inc (MGNX): Jon Marc Wigginton , Sr VP Clinical Dev & CMO of Macrogenics Inc sold 5,000 shares on Jul 1, 2016. The Insider selling transaction was reported by the company on Jul 6, 2016 to the Securities and Exchange Commission. The shares were sold at $27.22 per share for a total value of $136,100.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 6, 2016, Lynn Cilinski (VP, Controller and Treasurer) sold 8,922 shares at $27.22 per share price.On Mar 4, 2016, Paulo F Costa (director) purchased 10,000 shares at $17.20 per share price.Also, On Jan 6, 2016, Jon Marc Wigginton (Sr VP, Clinical) sold 10,000 shares at $29.64 per share price.On Nov 17, 2015, Ezio Bonvini (Senior VP, Research) sold 3,117 shares at $31.44 per share price.
Shares of MacroGenics Inc (MGNX) ended Tuesday, Jul 6, 2016 session in red amid volatile trading. The shares closed down -0.99 points or -3.64% at $26.2 with 2,15,454 shares getting traded. Post opening the session at $26.8, the shares hit an intraday low of $26.11 and an intraday high of $26.985 and the price vacillated in this range throughout the day. The company has a market cap of $905 M and the number of outstanding shares has been calculated to be 3,45,45,592 shares. The 52-week high of MacroGenics Inc is $39.9 and the 52-week low is $14.84.
MacroGenics Inc. is a biopharmaceutical company focused on discovering and developing antibody-based therapeutics for the treatment of cancer as well as various autoimmune disorders and infectious diseases. The Company develops new therapeutic product candidates using its antibody-based technology platforms and also in partnership with other biopharmaceutical companies. The Company has a pipeline of product candidates in human clinical testing primarily against various cancers. These include two product candidates developed using Fc Optimization platform namely margetuximab an antibody for the treatment of certain types of metastatic breast cancers and gastroesophageal cancers and MGA271 an antibody to impact various tumors through multiple potential mechanisms of action. In addition the Company has created different product candidates based on Dual-Affinity Re-Targetingr (DART) platform.